Search research articles
Contact Us
Filters
Showing results (71-80 of 85) with videos related to
Page
of 9
Sort By:
Echocardiography (Mount Kisco, N.Y.)
|
January 17, 2016
Right Heart Involvement in Patients with Sarcoidosis
Mita B Patel, Victor Mor-Avi, Gillian Murtagh, et al.
Hypertension (Dallas, Tex. : 1979)
|
May 16, 2023
Assessing the Accuracy of an Online Chat-Based Artificial Intelligence Model in Providing Recommendations on Hypertension Management in Accordance With the 2017 American College of Cardiology/American Heart Association and 2018 European Society of Cardiology/European Society of Hypertension Guidelines
Joseph Kassab, Joseph El Dahdah, Michel Chedid El Helou, et al.
Hypertension (Dallas, Tex. : 1979)
|
February 5, 2024
Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m<sup>2</sup>: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy
James A de Lemos, Bruno Linetzky, Carel W le Roux, et al.
JAMA Internal Medicine
|
November 24, 2025
Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial
Deborah B Horn, Bruno Linetzky, Melanie J Davies, et al.
Clinical Cardiology
|
July 30, 2024
Impact of the COVID-19 Pandemic on Conduct and Results of CLEAR Outcomes Trial
Abhayjit Singh, Luke J Laffin, Ashish Sarraju, et al.
European Journal of Preventive Cardiology
|
April 11, 2026
Effect of bempedoic acid in the absence of background lipid-lowering therapy on LDL cholesterol, hsCRP, and cardiovascular outcomes, among statin-intolerant patients: a post-hoc analysis of the CLEAR Outcomes trial
Carolina P Zingano, Danielle M Brennan, LeAnne Bloedon, et al.
Journal of the American College of Cardiology
|
November 9, 2022
Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers
Luke J Laffin, Dennis Bruemmer, Michelle Garcia, et al.
The New England Journal of Medicine
|
November 10, 2025
Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3
Luke J Laffin, Stephen J Nicholls, Russell S Scott, et al.
Circulation. Cardiovascular Imaging
|
January 15, 2016
Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction: Risk Stratification Using Cardiovascular Magnetic Resonance
Gillian Murtagh, Luke J Laffin, John F Beshai, et al.
The New England Journal of Medicine
|
April 23, 2025
Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension
Luke J Laffin, Branko Kopjar, Carrie Melgaard, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 85) with videos related to
Sort By:
Page
of 9
Echocardiography (Mount Kisco, N.Y.)
|
January 17, 2016
Right Heart Involvement in Patients with Sarcoidosis
Mita B Patel, Victor Mor-Avi, Gillian Murtagh, et al.
Hypertension (Dallas, Tex. : 1979)
|
May 16, 2023
Assessing the Accuracy of an Online Chat-Based Artificial Intelligence Model in Providing Recommendations on Hypertension Management in Accordance With the 2017 American College of Cardiology/American Heart Association and 2018 European Society of Cardiology/European Society of Hypertension Guidelines
Joseph Kassab, Joseph El Dahdah, Michel Chedid El Helou, et al.
Hypertension (Dallas, Tex. : 1979)
|
February 5, 2024
Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m<sup>2</sup>: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy
James A de Lemos, Bruno Linetzky, Carel W le Roux, et al.
JAMA Internal Medicine
|
November 24, 2025
Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial
Deborah B Horn, Bruno Linetzky, Melanie J Davies, et al.
Clinical Cardiology
|
July 30, 2024
Impact of the COVID-19 Pandemic on Conduct and Results of CLEAR Outcomes Trial
Abhayjit Singh, Luke J Laffin, Ashish Sarraju, et al.
European Journal of Preventive Cardiology
|
April 11, 2026
Effect of bempedoic acid in the absence of background lipid-lowering therapy on LDL cholesterol, hsCRP, and cardiovascular outcomes, among statin-intolerant patients: a post-hoc analysis of the CLEAR Outcomes trial
Carolina P Zingano, Danielle M Brennan, LeAnne Bloedon, et al.
Journal of the American College of Cardiology
|
November 9, 2022
Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers
Luke J Laffin, Dennis Bruemmer, Michelle Garcia, et al.
The New England Journal of Medicine
|
November 10, 2025
Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3
Luke J Laffin, Stephen J Nicholls, Russell S Scott, et al.
Circulation. Cardiovascular Imaging
|
January 15, 2016
Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction: Risk Stratification Using Cardiovascular Magnetic Resonance
Gillian Murtagh, Luke J Laffin, John F Beshai, et al.
The New England Journal of Medicine
|
April 23, 2025
Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension
Luke J Laffin, Branko Kopjar, Carrie Melgaard, et al.
Page
of 9